


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1-6 (cancelled)

7. (currently amended) ~~The method of claim 6~~ A method of synergistically enhancing the chemotherapeutic treatment of cancer expressing adenosine A<sub>3</sub> receptors comprising administering to a mammal, in need thereof, an effective amount of a high affinity adenosine A<sub>3</sub> receptor antagonist either prior to or during administration of a chemotherapeutic cancer agent characterized by developing P-glycoprotein (P-gp) or multi-drug resistance-associated protein (MRP) dependent multi-drug resistance (MDR), wherein the high affinity adenosine A<sub>3</sub> receptor antagonist has the effect of inhibiting the P-gp or MRP mediated drug-efflux thereby suppressing MDR, and wherein the high affinity adenosine A<sub>3</sub> receptor antagonist is a compound of the formula:



wherein:

A is ~~imidazole, pyrazole, or triazole~~;

R<sup>2</sup> is hydrogen, alkyl, substituted alkyl, alkenyl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl or aryl;

R<sup>3</sup> is furan;

R<sup>6</sup> is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle;

or a pharmaceutically acceptable salt thereof.

8. (currently amended) The method of claim 7 wherein R<sup>2</sup> is ~~selected from the group consisting of hydrogen, alkyl, alkenyl and aryl.~~

Claims 9 and 10 (cancelled)

11. (previously presented) The method of claim 7 wherein the cancer is selected from the group consisting of human leukemia, melanoma, pancreatic carcinoma, breast carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, lung carcinoma, histiocytic lymphoma, astrocytoma and keratinocytoma.

12. (currently amended) The method of claim ~~6~~ 7 wherein the cancer has multi-drug resistance that is P-glycoprotein dependent.

13. (previously presented) The method of claim 12 wherein the chemotherapeutic cancer agent is a taxane family compound.

14. (previously presented) The method of claim 12 wherein the chemotherapeutic cancer agent is a vinca alkaloid compound.

15. (previously presented) The method of claim 12 wherein the chemotherapeutic cancer agent is a camptothecin compound.

16. (previously presented) The method of claim 12 wherein the chemotherapeutic cancer agent is an antibiotic compound.

Claims 17-18 (cancelled)

19. (currently amended) The method of claim ~~48~~ 12 wherein  $R^2$  is ~~selected from the group consisting of hydrogen, alkyl, alkenyl and aryl.~~

Claims 20-27 (cancelled)

28. (currently amended) The method of claim ~~48~~ 19 wherein the chemotherapeutic cancer agent is a taxane family compound.

29. (currently amended) The method of claim ~~48~~ 19 wherein the chemotherapeutic cancer agent is a vinca alkaloid compound.

30. (currently amended) The method of claim ~~48~~ 19 wherein the chemotherapeutic cancer agent is a camptothecin compound.

31. (currently amended) The method of claim 48 19 wherein the chemotherapeutic cancer agent is an antibiotic compound.
32. (currently amended) The method of claim 48 19 wherein the cancer is selected from the group consisting of human leukemia, melanoma, pancreatic carcinoma, breast carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, lung carcinoma, histiocytic lymphoma, astrocytoma and keratinocytoma.
33. (new) The method of claim 32 wherein the high affinity adenosine A<sub>3</sub> receptor antagonist is selected from the group consisting of MRE3008F20, MRE3046F20, MRE3055F20, MRE3062F20, IL-10 and IL11.
34. (new) The method of claim 33 wherein the taxane family compound is selected from the group consisting of paclitaxel and docetaxel.
35. (new) The method of claim 33 wherein the vinca alkaloid compound is vinblastine.
36. (new) The method of claim 33 wherein the camptothecin compound is irinotecan.
37. (new) The method of claim 33 wherein the antibiotic compound is doxorubicin.
38. (new) The method of claim 19 wherein the high affinity adenosine A<sub>3</sub> receptor antagonist is selected from the group consisting of MRE3008F20, MRE3046F20, MRE3055F20, MRE3062F20, IL-10 and IL11.
39. (new) The method of claim 38 wherein the taxane family compound is selected from the group consisting of paclitaxel and docetaxel.
40. (new) The method of claim 38 wherein the vinca alkaloid compound is vinblastine.
41. (new) The method of claim 38 wherein the camptothecin compound is irinotecan.
42. (new) The method of claim 38 wherein the antibiotic compound is doxorubicin.